Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The USPTO routinely rejects claims as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback